Intravenous morphine plus acetaminophen provides greater early pain reduction and requires fewer rescue doses than morphine alone in the emergency department, a trial finds.

Evidence synthesis across randomized comparisons showed limited magnitude and duration of opioid analgesia for most acute pain presentations, challenging assumptions of broad short-term efficacy.

A sweeping review of previous research suggests commonly prescribed opioids often provide only modest pain relief and may increase side effect risk.

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

Dr. Edward Paul answers the question: 'How Does Chronic Pain Differ From Acute?' — -- Question: What Is Chronic Pain And How Does It Differ From Acute Pain? Answer: Chronic pain and acute pain ...

Credit: Getty Images Researchers assessed the safety and efficacy of suzetrigine, a non-opioid pain signal inhibitor, on moderate to severe acute pain from in patients with surgical and nonsurgical ...

The world's largest review of opioid pain relievers prescribed for acute pain found these medicines provide only small, short-term relief for some acute conditions and are ineffective for some others.

Pain has the potential to affect various aspects of a person’s life, from disrupting one’s daily routine to negatively impacting emotional well-being. It’s also one of the most common reasons that ...

Body pain treatment is required when an unpleasant body sensation that can signal actual or potential tissue damage occurs.

Chronic pain often gets the spotlight, but acute pain matters, too. Pain after surgery or an injury isn’t something to ignore or “power through” with the expectation that it’ll eventually go away.

New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...

SHANGHAI--(BUSINESS WIRE)--Xgene Pharmaceutical announced additional insights into the positive results of a multiple-center, placebo-controlled, dose-ranging Phase 2b study (registration number: ...